Trial reportTrials2011
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Trial report in Trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Study to Predict Optimised Treatment - in Depression
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 191 citations in OpenAlex.
- Magnetic resonance imaging for individual prediction of treatment response in major depressive disorder: a systematic review and meta-analysis.Translational psychiatry · 2021Pooled it
- Transient frontal spectral events from EEG predict antidepressant response to sertraline in depression.Journal of psychiatric research · 2026Trial
- A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Effects of 12-week escitalopram treatment on resting-state functional connectivity of large-scale brain networks in major depressive disorder.Human brain mapping · 2023Trial
- Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.Translational psychiatry · 2021Trial
- Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.Biological psychiatry · 2020Trial
- Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder.Molecular psychiatry · 2020Trial
- Trial
- Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial.Biological psychiatry · 2020Trial
- Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment.NeuroImage. Clinical · 2019Trial
- Heart rate variability as a biomarker of anxious depression response to antidepressant medication.Depression and anxiety · 2019Trial
- Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.Molecular psychiatry · 2018Trial
- Intrinsic functional connectivity predicts remission on antidepressants: a randomized controlled trial to identify clinically applicable imaging biomarkers.Translational psychiatry · 2018Trial
- Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.The American journal of psychiatry · 2018Trial
- Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.Journal of psychiatric research · 2016Trial
- Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.Translational psychiatry · 2016Trial
- Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.The lancet. Psychiatry · 2016Trial
- Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators. METHODS/
designThe International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65) from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden (secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half of the sample will be used to identify potential predictors and moderators, and the second half to replicate and confirm. DISCUSSION: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological predictors of treatment response in the largest known sample of MDD collected worldwide.
trial registrationInternational Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849. URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.